US EditionPublished • loading... • Updated
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
Investors who bought Dow Inc. securities from Jan 30 to Jul 23, 2025 may qualify to join the class action for alleged false financial statements.
- A class action lawsuit related to Altimmune, Inc.'s IMPACT Phase 2b MASH trial is underway, with a crucial deadline for lead plaintiff submissions set for early October 2025.
- The suit arose after Altimmune failed to meet a key statistical significance marker for fibrosis reduction and allegedly misrepresented trial results throughout the Class Period.
- Altimmune had promoted inflated expectations despite concealing higher placebo responses that negatively affected topline outcomes, leading investors to suffer damages when true data emerged.
- Rosen Law Firm, recognized as a top 4 global securities litigation firm since 2013, achieved recoveries exceeding $438 million for investors in 2019 and informs Altimmune shareholders of the opportunity to seek compensation without any upfront fees.
- The lawsuit indicates that individuals who bought Altimmune securities during the specified class period, ending June 25, 2025, may be eligible for compensation through court-approved contingency fee arrangements if they file to become lead plaintiff by the October 6, 2025 deadline.
Insights by Ground AI
26 Articles
26 Articles
ALT FINAL DEADLINE: ROSEN, A GLOBAL AND LEADING FIRM, Encourages Altimmune, Inc. Investors with Losses in Excess of $50K to Secure Counsel Before Important October 6 Deadline in Securities Class Action – ALT - Altimmune (NASDAQ:ALT)
Open the article to view the coverage from Benzinga
·New York, United States
Read Full Article
Henry Herald+13 Reposted by 13 other sources
DOW Deadline: DOW Investors with Losses in Excess of $50K Have Opportunity to Lead Dow Inc. Securities Fraud Lawsuit
·Georgia, United States
Read Full Article
Charleston Gazette-Mail+10 Reposted by 10 other sources
ALT Deadline: ALT Investors with Losses in Excess of $50K Have Opportunity to Lead Altimmune, Inc. Securities Fraud Lawsuit
NEW YORK, Oct. 2, 2025 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Altimmune, Inc. (NASDAQ: ALT) between August 10, 2023 and June 25, 2025, both dates inclusive (the "Class Period"), of…
·Charleston, United States
Read Full ArticleCoverage Details
Total News Sources26
Leaning Left3Leaning Right2Center6Last UpdatedBias Distribution55% Center
Bias Distribution
- 55% of the sources are Center
55% Center
L 27%
C 55%
R 18%
Factuality
To view factuality data please Upgrade to Premium
